Merck's Gardasil sales plunge as weak China demand, inventory issues and softer Japan trends cloud the vaccine's overall growth outlook in 2026.
Vaxcyte's new pneumococcal vaccine may only have phase 1/2 results behind it, but analysts are already predicting it could be a major competitor to rival shots from Pfizer and MSD. Just-reported data ...
The phase 2 trial of the new vaccine – known as PF-07872412 or 25vPnC – revealed stronger immune responses to the serotypes ...
Investor's Business Daily on MSN
How S&P drug titan Pfizer plans to outdo its own $6 billion franchise
The next-generation version of Pfizer's $6 billion pneumococcal vaccine franchise topped its predecessor in a midstage study.
Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.
Merck & Co., Inc. is currently listed on NYSE under MRK. One share of MRK stock can currently be purchased for approximately $122.41. Is Merck & Co., Inc. listed on the NASDAQ or NYSE? Merck & Co., ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results